Forecast Of The Day: Pfizer’s Oncology Revenue
What?
Pfizer’s (NYSE:PFE) Oncology Revenue, which includes revenues from Sutent, Xalkori, Inlyta, Ibrance, and other productions, rose from around $9 billion in 2019 to about $11 billion in 2020. We expect the metric to rise to around $12.6 billion in 2021 and $13.6 billion in 2022.
Why?
- Should You Pick Pfizer Stock At $30 After A 30% Fall In A Year?
- Should You Pick Pfizer Stock At $30?
- Down 25% In A Year Will Pfizer Stock Rebound To Its Pre-Inflation Shock Level?
- Will Pfizer Stock See Higher Levels Post Q1 Earnings?
- Is Pfizer Stock Undervalued At $40?
- This Logistics Company Appears To Be A Better Pick Over Pfizer Stock
Growth is being driven by market share gains for Ibrance, as well as the launch of new biosimilars.
So What?
We think the projected growth is largely priced into PFE stock. We value Pfizer at about $58 per share, roughly in line with the current market price.
See Our Complete Analysis For Pfizer
What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since the end of 2016.
Returns | Jan 2022 MTD [1] |
2022 YTD [1] |
2017-22 Total [2] |
PFE Return | -6% | -6% | 71% |
S&P 500 Return | -2% | -2% | 108% |
Trefis MS Portfolio Return | -7% | -7% | 265% |
[1] Month-to-date and year-to-date as of 1/13/2022
[2] Cumulative total returns since the end of 2016